FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2315761661> ?p ?o ?g. }

• W2315761661 abstract "Background: Potential flaws in the design of randomized controlled trials (RCTs) and their low generalizability to clinical practice are being increasingly discussed. As some recent RCTs in neuropathic pain, including postherpetic neuralgia (PHN), demonstrated moderate or no treatment effect, better understanding of factors that may improve trial design, effectiveness, and data interpretation is needed. Objective: To compare RCTs and a real-world study of gastroretentive gabapentin (G-GR) in PHN Methods: Data from two RCTs (Phase 3; n=359) and one real-world study (Phase 4; n=197) of patients with PHN who received G-GR 1800 mg once-daily. The Visual Analog Scale (VAS) and Brief Pain Inventory (BPI) were completed at baseline and the end of study. Patients’ Global Impression of Change (PGIC) was completed at the end of study. Results: Main differences in patient characteristics included higher baseline pain intensity on the VAS and BPI and no use of concomitant neuropathic pain medication in Phase 3. Reductions from baseline in the VAS (p=0.0201) and BPI pain scores (all p<0.05) were significantly greater in Phase 3 compared with Phase 4. In contrast, more patients reported “Very Much” or “Much” improvement on the PGIC in Phase 4 (p=0.0446). Similar proportion of patients experienced ≥1 AE (Phase 3, 54.6%; Phase 4, 50.8%), and AE incidence decreased rapidly to steady low levels after the 2-week titration. More patients discontinued treatment due to AEs during titration in Phase 4 (12.2% vs. 3.1%). Conclusion: To support evidence relevant to clinical practice in PHN and other neuropathic pain syndromes, real-world studies should be a standard complement to RCTs. Based on the RCT vs. real-world study comparison, management of AEs during titration seems important for achieving optimal treatment in clinical practice. For better trial design, measures of overall improvement (e.g., PGIC) should be considered as co-primary efficacy endpoints, along with pain intensity." @default.
• W2315761661 created "2016-06-24" @default.
• W2315761661 creator A5070767094 @default.
• W2315761661 date "2014-01-01" @default.
• W2315761661 modified "2023-10-18" @default.
• W2315761661 title "Randomized Controlled Trial versus Real-World Study in Postherpetic Neuralgia" @default.
• W2315761661 cites W1966600932 @default.
• W2315761661 cites W1972971739 @default.
• W2315761661 cites W1975340066 @default.
• W2315761661 cites W1976727358 @default.
• W2315761661 cites W1985668586 @default.
• W2315761661 cites W1987353610 @default.
• W2315761661 cites W1990014844 @default.
• W2315761661 cites W1992075998 @default.
• W2315761661 cites W2001464002 @default.
• W2315761661 cites W2004661376 @default.
• W2315761661 cites W2006976918 @default.
• W2315761661 cites W2013925555 @default.
• W2315761661 cites W2028934683 @default.
• W2315761661 cites W2039982019 @default.
• W2315761661 cites W2056755600 @default.
• W2315761661 cites W2060579001 @default.
• W2315761661 cites W2067766851 @default.
• W2315761661 cites W2076123673 @default.
• W2315761661 cites W2085662780 @default.
• W2315761661 cites W2094143311 @default.
• W2315761661 cites W2104089421 @default.
• W2315761661 cites W2104761404 @default.
• W2315761661 cites W2112473972 @default.
• W2315761661 cites W2112986908 @default.
• W2315761661 cites W2133526648 @default.
• W2315761661 cites W2157903425 @default.
• W2315761661 cites W2171274580 @default.
• W2315761661 cites W2410536927 @default.
• W2315761661 doi "https://doi.org/10.4172/2167-0846.1000154" @default.
• W2315761661 hasPublicationYear "2014" @default.
• W2315761661 type Work @default.
• W2315761661 sameAs 2315761661 @default.
• W2315761661 citedByCount "3" @default.
• W2315761661 countsByYear W23157616612014 @default.
• W2315761661 countsByYear W23157616612015 @default.
• W2315761661 crossrefType "journal-article" @default.
• W2315761661 hasAuthorship W2315761661A5070767094 @default.
• W2315761661 hasBestOaLocation W23157616611 @default.
• W2315761661 hasConcept C141071460 @default.
• W2315761661 hasConcept C142724271 @default.
• W2315761661 hasConcept C157585117 @default.
• W2315761661 hasConcept C168563851 @default.
• W2315761661 hasConcept C204787440 @default.
• W2315761661 hasConcept C2778866549 @default.
• W2315761661 hasConcept C556039675 @default.
• W2315761661 hasConcept C60644358 @default.
• W2315761661 hasConcept C71924100 @default.
• W2315761661 hasConcept C86803240 @default.
• W2315761661 hasConceptScore W2315761661C141071460 @default.
• W2315761661 hasConceptScore W2315761661C142724271 @default.
• W2315761661 hasConceptScore W2315761661C157585117 @default.
• W2315761661 hasConceptScore W2315761661C168563851 @default.
• W2315761661 hasConceptScore W2315761661C204787440 @default.
• W2315761661 hasConceptScore W2315761661C2778866549 @default.
• W2315761661 hasConceptScore W2315761661C556039675 @default.
• W2315761661 hasConceptScore W2315761661C60644358 @default.
• W2315761661 hasConceptScore W2315761661C71924100 @default.
• W2315761661 hasConceptScore W2315761661C86803240 @default.
• W2315761661 hasIssue "04" @default.
• W2315761661 hasLocation W23157616611 @default.
• W2315761661 hasOpenAccess W2315761661 @default.
• W2315761661 hasPrimaryLocation W23157616611 @default.
• W2315761661 hasRelatedWork W2052539084 @default.
• W2315761661 hasRelatedWork W2235574018 @default.
• W2315761661 hasRelatedWork W2507295142 @default.
• W2315761661 hasRelatedWork W2897370359 @default.
• W2315761661 hasRelatedWork W2953633878 @default.
• W2315761661 hasRelatedWork W2973537373 @default.
• W2315761661 hasRelatedWork W3159250744 @default.
• W2315761661 hasRelatedWork W4256514411 @default.
• W2315761661 hasRelatedWork W4292236216 @default.
• W2315761661 hasRelatedWork W2083697902 @default.
• W2315761661 hasVolume "03" @default.
• W2315761661 isParatext "false" @default.
• W2315761661 isRetracted "false" @default.
• W2315761661 magId "2315761661" @default.
• W2315761661 workType "article" @default.